Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide

Temozolomide (TMZ) is the main chemotherapeutic drug utilized for the treatment of glioblastoma multiforme (GMB), however, drug resistance often leads to tumor recurrence and poor outcomes. GMB cell lines were treated with TMZ for up to two weeks and then subjected to proteomics analysis to identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hai, Feng, Wenfeng, Lu, Yuntao, Li, Hezhen, Xiang, Wei, Chen, Ziyang, He, Minyi, Zhao, Liang, Sun, Xuegang, Lei, Bingxi, Qi, Songtao, Liu, Yawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931463/
https://www.ncbi.nlm.nih.gov/pubmed/27375225
http://dx.doi.org/10.1038/srep28948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931463/
https://www.ncbi.nlm.nih.gov/pubmed/27375225
http://dx.doi.org/10.1038/srep28948

Ejemplares similares